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CORRESPONDENCE
RESEARCH LETTER
Atorvastatin Does Not Alter Interferon
Beta–Induced Changes of Serum Matrix
Metalloproteinase 9 and Tissue Inhibitor
of Metalloproteinase 1 in Patients With
Multiple Sclerosis
I nterferon beta, the current cornerstone of multiplesclerosis (MS) therapy, was shown to reduce the ra-tio of matrix metalloproteinase 9 (MMP-9)–tissue in-
hibitor of metalloproteinase 1 (TIMP-1) in order to attenu-
ate overactive proteolysis and inhibit leukocyte migration.1-3
Matrix metalloproteinases, a family of extracellular matrix-
degrading enzymes, are involved in the pathogenesis of MS
by facilitating leukocyte migration, disruption of the blood-
brain barrier, processing of cytokines and their receptors,
and demyelination.1
Immunomodulatory properties of 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitors, includ-
ing atorvastatin, may be beneficial for the treatment of
MS. Among the immunomodulatory effects proposed for
statins, increased attention is drawn to the modulation
of MMPs. In vitro results suggest that statins may in-
crease MMP-9 activity and disrupt the proteolytic bal-
ance restored by interferon beta.1,4
In this study, we aimed to evaluate the treatment ef-
fects of interferon beta alone and in combination with
atorvastatin on parameters of proteolysis, ie, serum lev-
els of active MMP-9 and TIMP-1 and the active MMP-
9–TIMP-1 ratio in patients with relapsing-remitting MS.
Methods. Sequential serum samples were obtained from
28 patients (mean age, 33.4 years; mean Expanded Dis-
ability Status Scale score, 2.0) participating in the Swiss
Atorvastatin and Betaferon in Multiple Sclerosis Trial with
approval of the Cantonal Ethical Review Board (permit
17/05). In this study, patients with relapsing-remitting
MS are treated with interferon beta-1b monotherapy (250
µg every other day, subcutaneous) or with a combina-
tion of interferon beta-1b (250 µg every other day, sub-
cutaneous) and atorvastatin calcium (40 mg orally). All
of the included patients were treated de novo with in-
terferon beta for 3 months, prior to randomization to a
monotreatment or combination treatment (n=12 and
n=16, respectively). Patients in the Swiss Atorvastatin
and Betaferon in Multiple Sclerosis Trial were diag-
nosed with MS according to the McDonald criteria: dis-
ease duration of 3 months or longer, an Expanded Dis-
ability Status Scale score of 0 to 3.5 at baseline, and at
least 1 relapse in the past 2 years.5 A 1-month interval
between the last relapse and/or prednisone treatment was
mandatory for baseline enrollment of the respective pa-
tient. The control group consisted of 10 age-matched
healthy control subjects (mean age, 34.7 years) after ob-
taining informed consent.
Serum samples were collected by standard proce-
dures and stored at −80°C until use. Active MMP-9 and
TIMP-1 levels were determined with sandwich-type en-
zyme-linked immunosorbent assay kits (GE Health-
care, Buckinghamshire, England) that had been proven
reliable in MS studies.6 Special emphasis was paid to iden-
tical sample collection and processing conditions to mini-
mize possible interference by preanalytical variations.
Samples were diluted 1:40, and the detection limits were
0.5 ng/mL (active MMP-9) and 1.25 ng/mL (TIMP-1).
The comparisons between control subjects and patients
with MS (baseline) and intergroup treatment effects at
3, 6, and 9 months were performed with a Mann-
Whitney U test. Changes over time were evaluated with
a Wilcoxon signed rank test. P .05 was considered to
be statistically significant.
Results. In patients with MS, significantly higher levels
of active MMP-9 (P .001) (Figure, A) and a higher ac-
tive MMP-9–TIMP-1 ratio (P=.002) (Figure, E) were de-
tected at baseline as compared with the values found in
serum samples from control subjects. Serum levels of
TIMP-1 were significantly decreased in patients with MS
(P=.049) (Figure, C). After a 3-month treatment inter-
val with interferon beta, TIMP-1 levels were increased
in comparison with TIMP-1 levels at baseline before ini-
tiation of therapy (P=.003), whereas active MMP-9 lev-
els and the active MMP-9–TIMP-1 ratio were not al-
tered during this treatment interval. Serum levels of active
MMP-9 and TIMP-1 and the active MMP-9–TIMP-1 ra-
tio were not influenced by atorvastatin as an add-on treat-
ment during the study period (Figure, B, D, and F).
Comment.Here, we demonstrated a raised serum ratio of
active MMP-9–TIMP-1 (Figure, E) and an interferon beta–
induced increase of TIMP-1 levels (Figure, C) in patients
with MS. These findings are consistent with previous ob-
servations of proteolytic dysregulation in MS and stabili-
zationof theMMP-9–TIMP-1ratioby interferonbeta.6,7 Dur-
ing a study period of 9 months, no further alterations of
the proteolytic balance were observed with interferon beta
treatment. Ancillary atorvastatin treatment did not have any
additional effect on the interferon beta–induced antipro-
teolytic state. Hence, our results exclude both a detrimen-
tal neutralization and a synergistic effect on proteolysis by
adding atorvastatin to interferon beta therapy in patients
with relapsing-remitting MS.
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Figure. Mean (SEM) serum levels of active matrix metalloproteinase 9 (MMP-9) (A), tissue inhibitor of metalloproteinase 1 (TIMP-1) (C), and active
MMP-9–TIMP-1 ratio (E) in control subjects (n=10) and in patients with relapsing-remitting multiple sclerosis (MS) at baseline (n=28). Mean (SEM) serum levels
of active MMP-9 (B), TIMP-1 (D), and active MMP-9–TIMP-1 ratio (F) in patients with relapsing-remitting MS following either a monotherapy of interferon beta for
9 months (n=12) or a monotherapy of interferon beta for 3 months followed by a combination therapy of interferon beta and atorvastatin for 6 months (n=16).
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COMMENTS AND OPINIONS
Multiple Sclerosis and Recurrent
Disseminated Encephalomyelitis
Are Different Diseases
T he recent article by de Seze et al
1 correctly iden-
tifies a set of clinical signs and symptoms that may
be useful in differentiating acute disseminated
encephalomyelitis (DEM) from the first episode of mul-
tiple sclerosis (MS). However, their contention that
DEM may evolve or convert to MS implies that the 2
conditions are, if not identical, at least closely related. In
fact, they differ in at least 2 ways. Multiple sclerosis
occurs in people who are genetically vulnerable, a fea-
ture noticeably lacking in DEM. Even more importantly,
ever since Robert Carswell and Jean Cruveilhier pub-
lished their classic illustrations of MS almost 200 years
ago, the sharp edges of the typical MS lesion—so aptly
described by Ludo van Bogaert as de´coupe´es à l’emporte-
pièce—have been recognized by neuropathologists of the
caliber of Ivan Bertrand, Jean Gruner, and Franc¸ois
Lhermitte, to name just a few, as pathognomonic for
MS; they are never seen in DEM. It is difficult to accept
the concept that DEM would morph into a genetically
and pathologically dissimilar disease.
The authors seem to rely to a large extent on the se-
ries of cases by Schwarz et al,2 who rather simplistically
and inappropriately diagnosed DEM retrospectively based
solely on the lack of further episodes of neurological dys-
function. They also ignore the enormous literature de-
scribing the qualitative differences between the T2-
weighted magnetic resonance imaging lesions of DEM
and those of MS,3-6 relying only on purely quantitative
criteria despite their own description of the DEM le-
sions being widespread, multifocal, and extensive. Sur-
prisingly, they list 2 cases of MS as having spinal cord
lesions longer than 2 vertebral bodies despite the admo-
nition in the 2001 diagnostic criteria by McDonald et al7
that such lesions would strongly militate against the di-
agnosis of MS. Their use of the term multiphasic DEM is
confusing: I described multiphasic DEM6 as the occur-
rence of new signs or symptoms after an initial episode
of acute DEM, in contrast with recurrent DEM in which
there is a return of the same signs and symptoms pre-
sent in the first event. Finally, the cutoff point of 16 years
and the exclusion of children seem rather arbitrary be-
cause the general consensus is that MS is acquired early
in childhood. There is no convincing evidence that MS
and DEM in children are different from the adult con-
ditions.
The decision to start a lifelong regimen of immuno-
modulatory drugs is to be considered with great care; cer-
tainly, accuracy of diagnosis should be the principal con-
sideration.
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In reply
My coauthors and I thank Dr Poser for the interesting com-
ments. We agree with most of these remarks, but we think
that they are not applicable to clinical practice. We agree
that acute DEM is a different condition compared with MS;
however, as Dr Poser says, the 2 diseases are essentially dif-
ferent concerning genetic susceptibility and neuropatho-
logical data. If we consider the question to be a clinical point
of view, we are not able to use these parameters to distin-
guished the 2 diseases.
Charles M. Poser, MD, FRCP
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